ANRO has confirmed a bullish technical breakout with meaningful analyst-implied upside, but quality sitting well below the required floor, a volume-distribution divergence, and a choppy earnings track record keep this a speculative biotech name.
Thesis pillars
- Quality Below Required Floor→Stable
- Confirmed Breakout Momentum→Stable
- Volume Distribution Divergence→Stable
- +2 more pillars — see the Why tab for full reasoning
Alto Neuroscience, Inc. (ANRO) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.09: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 13.38; Below-average business quality.
Alto Neuroscience is a clinical-stage biopharmaceutical company advancing seven CNS product candidates for major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease, using an EEG-based Precision Psychiatry Platform for... Read more
Sell if holding. Engine safety override at $26.09: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 13.38; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Alto Neuroscience, Inc.
About Alto Neuroscience, Inc.
Alto Neuroscience is advancing seven clinical-stage neuropsychiatric assets, including lead program ALTO-207 for treatment-resistant depression, expected to begin a pivotal Phase 2b trial in the first half of 2026, without any FDA-approved products or product revenue. The company reported a $201.6 million accumulated deficit and $177.0 million in cash, cash equivalents, and restricted cash as of December 31, 2025, funding operations for at least the next 12 months.
Alto generates no product revenue; capital comes from public equity offerings, debt under a Loan and Security Agreement, and grant funding, including a Wellcome Trust Limited award supporting the ALTO-100 Phase 2b trial in bipolar depression. Its Precision Psychiatry Platform combines EEG, neurocognitive, and genomic data with machine learning to identify biomarker-defined patient subgroups intended to raise clinical-trial response rates, a strategy applied across compounds licensed from Stanford, Sanofi, Cerecor, Merck, Teva, and MedRx. ALTO-300 (agomelatine), already approved as an antidepressant in Europe and Australia, is being repositioned as an adjunctive U.S. MDD treatment defined by an EEG biomarker; ALTO-101, a transdermal PDE4 inhibitor for cognitive impairment in schizophrenia, holds FDA Fast Track designation. Licensing terms obligate Alto to milestone and royalty payments, including up to $102.0 million in commercial milestones owed to Sanofi and up to $59.1 million owed to Cerecor and Merck for ALTO-202.
Show full overview
Alto's near-term risk centers on a string of binary clinical readouts rather than a single asset: the ALTO-100 Phase 2b trial in MDD missed its primary endpoint in October 2024, though a pre-specified adjunctive subgroup showed a clinically meaningful signal (Cohen's d=0.47, p=0.09) now being tested in bipolar depression. ALTO-101's Phase 2 proof-of-concept data in cognitive impairment associated with schizophrenia is expected around the end of the first quarter of 2026, and ALTO-300's Phase 2b topline data in MDD is expected in mid-2026. A miss on any of these could weigh on the biomarker-based platform thesis broadly, since each trial doubles as validation of Alto's patient-selection approach, not just of the individual molecule.
See also: Healthcare · Biotechnology
From Alto Neuroscience, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-05-28Item 5.02LOWBoard appointed Andrew Miller, Ph.D. (Karuna Therapeutics founder) as a Class III director effective May 27, 2026, filling a vacancy from a board expansion to seven members; routine appointment.SEC filing →
- 2026-05-13Item 5.02LOWBoard adopted an Amended and Restated 2024 Employee Stock Purchase Plan on March 16, 2026, subsequently approved by stockholders at the May 12, 2026 annual meeting; routine equity plan amendment.SEC filing →
- 2026-05-13Item 5.07LOWAt the May 12, 2026 annual meeting, stockholders voted on four proposals including approval of the Amended and Restated 2024 ESPP; approximately 83.77% of shares outstanding were represented.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.09: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Elevated put/call ratio: 13.38; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.26. Score 5.5/10, moderate confidence.
Take-profit target: $30.56 (+17.1% upside). Prior stop was $24.26. Stop-loss: $24.26.
Quality below floor (1.6 < 4.0).
Alto Neuroscience, Inc. trades at a P/E of N/A (forward -7.6). TrendMatrix value score: 7.5/10. Verdict: Sell.
18 analysts cover ANRO with a consensus score of 4.4/5. Average price target: $35.
What does Alto Neuroscience, Inc. do?Alto Neuroscience is a clinical-stage biopharmaceutical company advancing seven CNS product candidates for major...
Alto Neuroscience is a clinical-stage biopharmaceutical company advancing seven CNS product candidates for major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease, using an EEG-based Precision Psychiatry Platform for biomarker-driven patient selection. The company has no approved products or product revenue, reporting a $201.6 million accumulated deficit as of December 31, 2025, and funds operations through equity, debt, and licensing arrangements with Sanofi, Cerecor, Merck, Teva, and MedRx.